KRAS and familial pancreatic carcinoma: This combination has been explored in patients with EGFR mutant pretreated NSCLC, triple-negative breast cancer, pancreatic cancer, colorectal cancer, malignant melanoma, NSCLC and other advanced solid tumors with KRAS, NRAS and/or B-RAF mutations; the results are not available yet.